Today

Agents

Chat

Arena

Discover

More

App

Halozyme Therapeutics Q2 Adjusted EPS USD 2.28 Vs. IBES Estimate USD 1.84 - HALO News | Rallies

Halozyme Therapeutics Q2 Adjusted EPS USD 2.28 Vs. IBES Estimate USD 1.84

HALO•2026-08-06

Q2 results

Halozyme Therapeutics Q2 operating income was USD 287.7 million.

Q2 net income: USD 229.9 million
Q2 EPS: USD 1.9
Q2 adjusted EPS: USD 2.28 vs. IBES estimate of USD 1.84

Related News

Transcontinental Realty Q2 swings to net loss on higher operating expenses, lower interest income

TCI•2026-08-06

JBT Marel declares quarterly dividend of $0.10 a share

JBTM•2026-08-06

Stagwell director Beth J. Kaplan files initial beneficial ownership statement

•

2026-08-06

Roku beats quarterly revenue estimates on advertising, subscriptions strength

ROKU•2026-08-06

Ready Capital Q2 EPS USD -0.63

RC•2026-08-06